Christopher Ogden - Feb 4, 2025 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Financial Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Stock symbol
CTMX
Transactions as of
Feb 4, 2025
Transactions value $
$0
Form type
4
Date filed
2/6/2025, 05:55 PM
Previous filing
Aug 22, 2024
Next filing
Mar 20, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +44K +40.71% $0.00 152K Feb 4, 2025 Direct F1
transaction CTMX Common Stock Award $0 +57.5K +37.81% $0.00 210K Feb 4, 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Stock Option (Right to Buy) Award $0 +225K $0.00 225K Feb 4, 2025 Common Stock 225K $0.86 Direct F4
transaction CTMX Stock Option (Right to Buy) Award $0 +115K $0.00 115K Feb 4, 2025 Common Stock 115K $0.86 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date.
F2 Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date.
F3 Includes 179,310 RSUs.
F4 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
F5 1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.